British Biotech--on the Road to Recovery?

British Biotech, whose product setbacks and management missteps reduced its credibility to tatters and knocked the valuations of the UK biotech industry, is trying to rebuild itself, thanks to out-licensing deals with Schering-Plough and Serono, an in-licensing program designed to take advantage of its existing clinical infrastructure, and a shift towards anti-infectives.